Ratings Sectra AB

Equities

SECT B

SE0020539310

Real-time Estimate Cboe Europe Other stock markets 09:14:50 2024-04-23 am EDT			5-day change	1st Jan Change
213.1 ^SEK	+3.35%		+2.80%	+18.27%

Mar. 14	Halton Healthcare Selects Sectra's Cloud SaaS to Optimize Enterprise Imaging Workflows and Strengthen Security	CI
Mar. 12	Homerton Healthcare in the UK Achieves Milestone with Sectra Imaging Technology	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With an expected P/E ratio at 97.49 and 80.86 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
Most analysts recommend that the stock should be sold or reduced.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SECTRA AB	+18.27%	3.64B		B-
VEEVA SYSTEMS INC.	+3.40%	32.12B		C
PRO MEDICUS LIMITED	+11.88%	7B		C-
EVOLENT HEALTH, INC.	-9.60%	3.4B		C-
OMNICELL, INC.	-25.11%	1.29B		B
LUNIT INC.	-34.43%	1.12B		-
SIMULATIONS PLUS, INC.	+0.56%	899M		C
VERADIGM INC.	-26.79%	827M	-	C+
B-SOFT CO.,LTD.	-42.14%	808M		-
SURGICAL SCIENCE SWEDEN AB	-17.64%	707M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes